Preclinical & Clinical Assets

Biocytogen is dedicated to the discovery and development of novel antibody-based drugs to meet unmet medical needs, with a particular focus on oncology, autoimmune, inflammatory, metabolic, and other diseases. The company’s current assets include monoclonal antibodies, bispecific antibodies, bispecific ADCs, etc. By advancing its R&D capabilities and establishing key partnerships for licensing and co-development opportunities, Biocytogen aims to deliver transformative therapies to patients in need.

To learn more about our assets, or to explore licensing/co-development opportunities. please contact [email protected].

Candidate

Target

Combination

Indication

Phase

Upcoming Milestone

Rights

News/Press Release



Clinical-stage Drug Candidates
 


YH003



CD40



PD-1 Melanoma Global MRCT

Phase II

2022 Q4 Complete Recruitment Global Biocytogen/Eucure Biopharma Announce First Patient Dosed in Phase II Clinical Trial of YH003 Combination Therapy as a First-Line Treatment for Mucosal Melanoma



PD-1 Pancreatic
cancer
Global MRCT

Phase II

2022 Q4 Complete  Recruitment
Monotherapy
Solid tumors China  Phase I 2022 Q2 Patient
Recruitment
PD-1+
YH001
Solid tumors Australia

IND

2023 Q1 Complete Recruitment
PD-1 Mucosal  melanoma China 2022 Q3 Complete Recruitment
YH001


CTLA-4


PD-1 Non-small-cell
lung cancer
(NSCLC)
Global MRCT

Phase II

2023 Q1 Patient
Recruitment
Global


Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting


PD-1 Hepatocellular
carcinoma
(HCC)
Global MRCT

Phase II

 

2023 Q1 Patient
Recruitment
Monotherapy Solid tumors China 

Phase I

2022 Q2  Complete Site Visit
PD-L1 Sarcoma  Global MRCT 2022 Q3 Patient
Recruitment
YH002


OX40


Monotherapy  Solid Tumors Australia

Phase 1

2022 Q3
Complete Phase I
trial
Global First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia
Monotherapy Solid Tumors China/USA

Phase 1

Launch based on
clinical results in
Australia
YH001 Solid Tumors China/Australia

Phase I

2023 Q1 Complete Recruitment
YH004

4-1BB

PD-1 Hematological
malignancies
Australia

Phase 1

2023 Q4 Complete Recruitment Global
PD-1 Solid tumors Australia/China

Phase 1

 

2023 Q4 Complete Recruitment
YH005-ADC Claudin18.2-
ADC
Solid tumors Australia

IND -> Phase 1

Remegen
Developmental -stage Drug Candidates
 
 
 
YH008 PD-1/CD40
(bispecific
antibody)
  Solid tumors CMC Global 
YH006 CTLA-4/
OX40
(bispecific
antibody)
  Solid Tumors CMC   Global    
YH009 RSV   Prevention/
Treatment for
RSV infection 
CMC Global 
YH010 PD-L1/IL-12   Solid Tumors Discovery   Global    
YH011 PD-L1/
cytokine
  Solid Tumors Discovery   GeneQuantum Healthcare  
YH012 Bispecific
antibody
ADC
  Solid tumors Discovery   Global   
YH013 Bispecific
antibody
ADC
Solid tumors Discovery Global 

 

Back to top